LOGIN  |  REGISTER
Viking Therapeutics
Amneal Pharmaceuticals

CooperCompanies to Participate in the Jefferies Global Healthcare Conference

May 15, 2024 | Last Trade: US$74.77 1.93 -2.52

SAN RAMON, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, will participate in the Jefferies Global Healthcare Conference on Wednesday, June 6, 2024. Brian Andrews, Executive Vice President, Chief Financial Officer & Treasurer, will represent the Company in a session scheduled at 1:30 PM ET.

The webcast will be available to investors and other interested parties by accessing the CooperCompanies’ website at http://investor.coopercos.com.

About CooperCompanies

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies (“Cooper”) has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.

Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page